The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients
Ao Zeng, Zhilong Xu, Abudumijiti Abuduwayiti, Jiarui Wang, Yanze Yin, Keyi Chen, Mengtao Wang, Xiao Zhou, Jie Dai · 2026
Read The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients by Ao Zeng, Zhilong Xu, Abudumijiti Abuduwayiti, Jiarui Wang, Yanze Yin, Keyi Chen, Mengtao Wang, Xiao Zhou, Jie Dai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263859.txt.
Description
Ao Zeng and colleagues checked in 2026 whether drug treatment before lung cancer surgery harms or helps breathing capacity, a worry for patients who must then lose part of a lung. Their series covered 253 patients who received chemotherapy plus immune therapy, then surgery, between 2019 and 2023. Lung function was measured before and after the drug phase.
Breathing capacity rose rather than fell: the key one-second airflow measure climbed noticeably across the group. Patients with chronic obstructive pulmonary disease, about twenty-eight percent of the cohort, improved the most. Their gain in airflow roughly doubled that of patients without the condition, regardless of any collapsed lung segments. Statistical modeling kept the lung disease diagnosis as an independent predictor of improvement. The authors suggest treatment can reopen airways enough to make surgery possible for some patients previously judged too frail.
Catalog record
| CREATOR | Ao Zeng, Zhilong Xu, Abudumijiti Abuduwayiti, Jiarui Wang, Yanze Yin, Keyi Chen, Mengtao Wang, Xiao Zhou, Jie Dai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |